Build a reference frame, save a practice trade, or preview a draft. No brokerage order is placed.
Paper trade unavailable: missing risk-bounded frame
Reference only. Not financial advice. No brokerage order is placed.
Why $ABBV?
ABBV5WATCHpharma
Quantitative
Revenue (CY2026Q2): $16.99B (+10.2% YoY)
Net Income (CY2026Q2): $3.61B (+285.2% YoY)
Net Margin (CY2026Q3): 24.2%
Catalysts
Clinical trial milestone: Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene L
Clinical trial milestone: Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
Risks
Position-sizing discipline: Conviction WATCH (5 score) — size accordingly; no specific catalyst-fade risk flagged
Bear case
Multiple compression: If breadth deteriorates, pharma-wide multiples re-rate lower regardless of pick-specific thesis
Tickers Catalyst Edge tracks as moving with this name. Cross-correlation derived from sector + score-cohort proximity.
Earnings Catalyst
No recent earnings event.
Auto-generated from public filings + tier-1 wires. Catalyst Edge publishes its picks and its losses — see the trust report and methodology.
Not financial advice. Confirm independently before trading.
You came here for ABBV. You found it after it moved, the same way everyone else did.
$99 once — every ticker on this site ranked before the open.